SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,486,183 | -17.0% | 117,717 | 0.0% | 0.10% | -15.9% |
| Q4 2022 | $2,995,898 | +175.6% | 117,717 | +108.4% | 0.11% | +162.8% |
| Q2 2022 | $1,087,000 | +10.7% | 56,480 | 0.0% | 0.04% | +26.5% |
| Q1 2022 | $982,000 | +30.4% | 56,480 | -60.6% | 0.03% | +9.7% |
| Q1 2019 | $753,000 | -15.4% | 143,438 | -28.3% | 0.03% | -18.4% |
| Q4 2018 | $890,000 | -44.9% | 200,000 | 0.0% | 0.04% | -35.6% |
| Q3 2018 | $1,616,000 | +15.1% | 200,000 | 0.0% | 0.06% | +11.3% |
| Q2 2018 | $1,404,000 | -50.7% | 200,000 | 0.0% | 0.05% | -52.3% |
| Q1 2018 | $2,846,000 | +62.4% | 200,000 | 0.0% | 0.11% | +63.2% |
| Q4 2017 | $1,752,000 | -25.1% | 200,000 | 0.0% | 0.07% | -19.0% |
| Q3 2017 | $2,340,000 | -16.2% | 200,000 | 0.0% | 0.08% | -19.2% |
| Q2 2017 | $2,794,000 | – | 200,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |